Veraxa Biotech names Carl von Halem interim CFO, replacing Torsten Bürgermeister
VRXA•Interim CFO appointment
Veraxa Biotech appointed Carl von Halem as interim chief financial officer, replacing Torsten Bürgermeister.
Von Halem’s background
Von Halem is CFO of Xlife Sciences, where he helped take Veraxa public and worked on the Nasdaq listing process.
He also serves as managing director of Xlife Science GmbH, with prior experience as co-founder and COO of fintech CommneX.
Search for permanent finance chief
Management is in late-stage talks with a permanent CFO candidate to support the next phase of expansion and operational growth.
